QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Fibrocell Science, Inc. (FCSC) to Host Investor Conference Call to Discuss Growth Strategy 0 comments
    Aug 24, 2011 9:31 AM | about stocks: FCSC

    On Tuesday, Fibrocell Science, Inc. announced that Mr. David Pernock, their Chairman and Chief Executive Officer, will host an investor conference call to provide a business update and discuss its growth strategy. This call will take place today, Wednesday, August 24, 2011, at 4:30 PM Eastern Time. Fibrocell Science, Inc. is a cell therapy company focusing on the development of autologous (personalized) cell therapies for aesthetic, medical, and scientific applications.
    Fibrocell Science, Inc. invites all interested parties to join the call by dialing 888-500-6974 for domestic participants and 719-457-2657 for international participants. They will also broadcast the call live over the Internet. The investor conference call can be accessed on the Investors section of Fibrocell Science’s website at fibrocellscience.com.

    A telephone replay will be available for two weeks following the call by dialing 877-870-5176 for domestic participants and 858-384-5517 for international participants. When prompted, the Company requests that those interested enter replay pin number 7372734. For those who are not available to listen to the live webcast, the call will be archived for 90 days on Fibrocell Science, Inc.’s corporate website.
    Headquartered in Exton, Pennsylvania, Fibrocell Science, Inc. is a biotechnology company that lists on the OTC Bulletin Board. The Company focuses on the development of regenerative cell therapy for aesthetic, medical, and scientific applications. The Company’s commitment is to advancing the scientific, medical, and commercial potential of autologous skin and tissue, and their innovative cellular processing technology and manufacturing excellence.

    In June, Fibrocell Science, Inc. announced the approval of LAVIV® (azficel-T) for the treatment of moderate to severe nasolabial folds. LAVIV® is the first and only cell based product for aesthetics. The Company is prepared to make LAVIV® available in the U.S. market shortly. LAVIV® is made from one’s own skin cells. These are used to improve the appearance of wrinkles that go from the sides of an individual’s nose to the corners of their mouth (called nasolabial folds).

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: FCSC
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.